Gulbransen Graham, Xu William, Arroll Bruce
Private Practitioner, Cannabis Care NZ, West Care Specialist Centre, Auckland, New Zealand
Medical Student, Department of General Practice and Primary Health Care, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
BJGP Open. 2020 May 1;4(1). doi: 10.3399/bjgpopen20X101010. Print 2020.
Cannabidiol (CBD) is the non-euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear.
To review the changes in self-reported quality of life measurements, drug tolerability, and dose-dependent relationships in patients prescribed CBD oil for various conditions at a single institution.
DESIGN & SETTING: An audit including all patients ( = 400) presenting to Cannabis Care, New Zealand, between 7 December 2017 and 7 December 2018 seeking CBD prescriptions METHOD: Indications for CBD use were recorded at baseline. Outcomes included EuroQol quality of life measures at baseline and after 3 weeks of use, patient-reported satisfaction, incidence of side effects, and patient-titrated dosage levels of CBD.
Four hundred patients were assessed for CBD and 397 received a prescription. Follow-up was completed on 253 patients (63.3%). Patients reported a mean increase of 13.6 points (<0.001) on the EQ-VAS scale describing overall quality of health. Patients with non-cancer pain and mental-health symptoms achieved improvements to patient-reported pain and depression and anxiety symptoms (<0.05). There were no major adverse effects. Positive side effects included improved sleep and appetite. No associations were found between CBD dose and patient-reported benefit.
There may be analgesic and anxiolytic benefits of CBD in patients with non-cancer chronic pain and mental health conditions such as anxiety. CBD is well tolerated, making it safe to trial for non-cancer chronic pain, mental health, neurological, and cancer symptoms.
大麻二酚（CBD）是大麻中不产生欣快感的成分。2017年，新西兰对《药物滥用条例》（1977年）进行了修订，允许医生开具CBD处方。CBD的治疗益处和耐受性仍不明确。
回顾在单一机构中，为各种病症开具CBD油处方的患者自我报告的生活质量测量、药物耐受性和剂量依赖性关系的变化。
一项审计，纳入了2017年12月7日至2018年12月7日期间前往新西兰大麻护理中心寻求CBD处方的所有患者（n = 400）。方法：在基线时记录CBD的使用指征。结果包括基线时和使用3周后的欧洲生活质量量表测量结果、患者报告的满意度、副作用发生率以及患者自行调整的CBD剂量水平。
对400名患者进行了CBD评估，397名患者获得了处方。253名患者（63.3%）完成了随访。患者报告在描述总体健康状况的EQ-VAS量表上平均增加了13.6分（P<0.001）。患有非癌性疼痛和心理健康症状的患者在患者报告的疼痛、抑郁和焦虑症状方面有所改善（P<0.05）。没有重大不良反应。积极的副作用包括睡眠和食欲改善。未发现CBD剂量与患者报告的益处之间存在关联。
CBD对患有非癌性慢性疼痛和心理健康状况（如焦虑）的患者可能具有镇痛和抗焦虑作用。CBD耐受性良好，使其可安全用于非癌性慢性疼痛、心理健康、神经和癌症症状的试验。
